Minerva Neurosciences reported $3.08M in Current Liabilities for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 88.22M 7.11M
Adma Biologics ADMA:US $ 32.34M 14.15M
ALKERMES ALKS:US $ 452.98M 69.54M
Arena Pharmaceuticals ARNA:US $ 53.36M 11.48M
AstraZeneca AZN:LN 23649M 1427M
Bristol Myers Squibb BMY:US $ 21460M 2469M
Dynavax Technologies DVAX:US $ 528.93M 324.29M
Eli Lilly And LLY:US $ 13682M 1411.2M
Esperion Therapeutics ESPR:US $ 78.48M 4.16M
GlaxoSmithKline GSK:LN 22417M 1030M
Halozyme Therapeutics HALO:US $ 113.15M 1.1M
Kindred Biosciences KIN:US $ 11.26M 4.71M
Marinus Pharmaceuticals MRNS:US $ 37.68M 20.98M
Minerva Neurosciences NERV:US $ 3.08M 1.36M
Neurocrine Biosciences NBIX:US $ 225.9M 13M
Novartis NOVN:VX SF 29880M 247M
Novavax NVAX:US $ 1753.42M 101.9M
Takeda 4502:JP Y 1918750M 273984M
Vanda Pharmaceuticals VNDA:US $ 72M 0.01M